https://www.selleckchem.com/mTOR.html
This article summarizes the FDA review and the data supporting the approval of ado-trastuzumab emtansine as a component of treatment for patients with HER2-positive EBC with residual disease. Copyright ©2020, American Association for Cancer Research.Matched pre-/post-treatment tissue biopsies from EGFR-mutant NSCLC patients demonstrate that histologic transformations, including both SCLC and squamous transformation, are unexpectedly common among patients progressing on first-line osimertinib. The study highlights the key role of tissue testing and
Beğen
Yorum Yap
Paylaş
